# CGM Data Analysis Summary - Patient R016 v5

**Analysis Date:** 2025-08-14  
**Data Source:** `/Users/williamsun/Library/CloudStorage/OneDrive-Personal/AA唐宝图 Pro/AA数据业务/质肽生物/ZT002-揭盲/ZT002-Id_IIa-CGM导出数据_txt_20240730/Placebo-V5/R016 v5.txt`

## Data Collection Overview
- **Duration:** 13 days, 22 hours, 30 minutes (March 18, 2024 10:25 - April 1, 2024 08:55)
- **Total Data Points:** 1,339 readings
- **Data Completeness:** 100.1% (excellent coverage)
- **Average Interval:** 15.0 minutes (standard CGM frequency)

## Basic Glucose Statistics
| Metric | Value | Unit |
|--------|--------|------|
| Mean | 9.12 | mmol/L |
| Median | 9.00 | mmol/L |
| Standard Deviation | 2.52 | mmol/L |
| Coefficient of Variation | 27.61 | % |
| Minimum | 3.10 | mmol/L |
| Maximum | 18.60 | mmol/L |
| Range | 15.50 | mmol/L |
| Interquartile Range | 3.50 | mmol/L |

## Dual Variability Analysis

### 1. Glucose CV (Overall Blood Glucose Stability)
- **Value:** 27.62%
- **Interpretation:** Low variability (excellent glucose stability)
- **Clinical Significance:** CV < 29% indicates good metabolic control

### 2. Percentile Band CV (Circadian Rhythm Stability) 
- **Value:** 36.48%
- **Median CV across time slots:** 15.25%
- **Mean percentile band width:** 2.81 mmol/L
- **Clinical Significance:** Moderate circadian variability

## AGP-Style Analysis (Time in Range)
| Range | Percentage | Target | Status |
|-------|------------|---------|---------|
| Very Low (<3.0 mmol/L) | 0.0% | <1% | ✅ Excellent |
| Low (<3.9 mmol/L) | 0.8% | <4% | ✅ Good |
| Tight Target (3.9-7.8 mmol/L) | 35.0% | - | - |
| Standard Target (3.9-10.0 mmol/L) | 63.4% | >70% | ⚠️ Below target |
| High (>10.0 mmol/L) | 35.8% | <25% | ❌ Above target |
| Very High (>13.9 mmol/L) | 3.1% | <5% | ✅ Acceptable |

## Advanced Variability Metrics
- **Mean Absolute Glucose (MAG):** 0.43 mmol/L
- **J-Index:** 43.87
- **High Blood Glucose Index (HBGI):** 1.04
- **Low Blood Glucose Index (LBGI):** 0.88

## Glucose Episodes Analysis

### Hypoglycemic Episodes
- **Total hypoglycemic readings (<3.9 mmol/L):** 11 (0.8%)
- **Number of hypoglycemic episodes:** 3
- **Severe hypoglycemic readings (<3.0 mmol/L):** 0 (0.0%)

**Episode Details:**
1. **Episode 1:** March 24-25, 23:40-01:25 (120 minutes, min: 3.5 mmol/L)
2. **Episode 2:** March 27, 20:10 (15 minutes, min: 3.8 mmol/L)  
3. **Episode 3:** April 1, 01:25 (15 minutes, min: 3.8 mmol/L)

### Hyperglycemic Episodes
- **Hyperglycemic readings (>10.0 mmol/L):** 479 (35.8%)
- **Severe hyperglycemic readings (>13.9 mmol/L):** 42 (3.1%)

## Circadian Patterns
- **Peak glucose hour:** 10:00 AM (Mean: 11.7 mmol/L)
- **Trough glucose hour:** 01:00 AM (Mean: 6.9 mmol/L)
- **Most variable hour:** 01:00 AM (CV: 29.0%)
- **Dawn phenomenon:** 1.7 mmol/L rise from 3 AM to 6 AM

## Clinical Risk Assessment
- **Variability Risk Level:** Low (CV: 27.6%)
- **Overall Glycemic Assessment:** Acceptable glycemic control
- **Primary Concern:** TIR below recommended 70%

## Clinical Recommendations

### Medium Priority
1. **TIR Optimization:** Time in range (63.4%) is below the 70% target
   - Consider adjusting basal insulin or medication timing
   - Review meal composition and timing patterns

2. **Hypoglycemia Management:** 3 hypoglycemic episodes detected
   - Review basal insulin doses, particularly for overnight periods
   - Consider continuous glucose monitoring alerts for low glucose

### Positive Findings
- ✅ Excellent glucose stability (low CV of 27.6%)
- ✅ No severe hypoglycemia (<3.0 mmol/L)
- ✅ Severe hyperglycemia within acceptable limits (3.1% < 5%)
- ✅ Excellent data completeness

## Key Clinical Insights

1. **Glucose Stability:** The patient demonstrates excellent glucose stability with a CV of 27.6%, indicating good metabolic control without excessive fluctuations.

2. **Circadian Variation:** Moderate circadian variability (36.48% percentile band CV) suggests room for improvement in meal timing or medication scheduling.

3. **Hyperglycemia Pattern:** The 35.8% time above 10.0 mmol/L indicates postprandial glucose management could be optimized.

4. **Safety Profile:** Very low hypoglycemia risk with only 0.8% time below 3.9 mmol/L and no severe hypoglycemia.

5. **Dawn Phenomenon:** Present but moderate (1.7 mmol/L rise), suggesting some insulin resistance in early morning hours.

## Conclusion

Patient R016 v5 shows **acceptable glycemic control** with excellent glucose stability. The primary area for improvement is increasing time in range from 63.4% to the target >70%. The low hypoglycemia risk and good glucose stability provide a safety margin for potential intensification of glucose management to improve TIR.

**Risk-Benefit Assessment:** Low risk profile allows for careful glucose management optimization to improve time in range while maintaining excellent glucose stability.